Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast discussions on two panels on which members of its senior management team will participate at the RBC Capital Conference on December 14, 2006.

George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories and Chief Scientific Officer of Regeneron, will participate on the New Antibody Technology panel on December 14 at 1:00 pm (ET). Neil Stahl, Ph.D., Senior Vice President, Therapeutics and Clinical Program Development, will participate on the Eyeing the Future of AMD panel on December 14 at 11:00 am (ET). The panel discussions will be broadcast live and may be accessed through the Company's website (www.regeneron.com on the Events page, under the Investor Relations heading) at the time of the presentation. Archived versions of the panel discussions will be available after the live webcast through January 13, 2007.

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.

Additional information about Regeneron and recent news releases are available on Regeneron's worldwide web site at www.regeneron.com